Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 41

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H2 2018

Summary

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Metabotropic glutamate receptor 4 is a protein encoded by the GRM4 gene. It is a G-protein coupled receptor for glutamate. Glutamate binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling inhibits adenylate cyclase activity.

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System and Immunology which include indications Parkinson's Disease, Multiple Sclerosis, Opium (Opioid) Addiction, Anxiety Disorders, Autoimmune Disorders, Depression, Dyskinesia, Infantile Spasm (West Syndrome), Obsessive-Compulsive Disorder, Psychosis, Status Epilepticus and Substance (Drug) Abuse.

The latest report Metabotropic Glutamate Receptor 4 - Pipeline Review, H2 2018, outlays comprehensive information on the Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)

- The report reviews Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics and enlists all their major and minor projects

- The report assesses Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Overview
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Domain Therapeutics SA
H. Lundbeck AS
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Drug Profiles
ADX-88178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
foliglurax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JBPOS-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LSP-29166 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize mGluR4 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize mGLUR4 for Parkinson's Disease, Multiple Sclerosis and Autoimmune Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0418506 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Dormant Products
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Product Development Milestones
Featured News & Press Releases
Mar 20, 2018: Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by the French biotech
Jul 10, 2017: Parkinson's disease: Prexton announces initiation of phase II clinical testing
Oct 11, 2016: Addex Initiates New Study in Collaboration with US National Institute of Drug Abuse with ADX88178 in Non-Human Primate Model of Cocaine Addiction
Sep 19, 2016: Parkinson's disease: Prexton Therapeutics completes phase 1 clinical trial
Jun 13, 2016: Addex mGluR4 Program Demonstrates Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases
Mar 07, 2016: Parkinson's disease: Prexton Therapeutics starts phase 1 clinical trial
Dec 09, 2015: Addex Scientists Publish New Data Supporting the Potential of mGlu4 Receptor Positive Allosteric Modulators in Multiple Sclerosis
Nov 23, 2015: Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR4 Allosteric Modulator for Neurodegenerative and Psychiatric Diseases
Oct 02, 2012: Addex Therapeutics And Collaborators Receive CHF700,000 Grant To Develop Allosteric Modulators For Neurodegenerative And Psychiatric Diseases
Sep 24, 2012: Addex Therapeutics's mGluR4 Allosteric Modulator Found To Be Effective In Multiple Sclerosis Model
Jul 16, 2012: Addex Announces Publication Of Positive Data On Efficacy Of New Drug To Treat Parkinson's Disease In Journal Of Pharmacology And Experimental Therapeutics
Jul 10, 2009: Addex In Collaboration With Merck & Co., Inc. Achieves Second Milestone In Parkinson´s Disease
Feb 25, 2008: Addex In Collaboration With Merck & Co., Inc. Achieves First Milestone In Parkinson's Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Addex Therapeutics Ltd, H2 2018
Pipeline by Domain Therapeutics SA, H2 2018
Pipeline by H. Lundbeck AS, H2 2018
Dormant Projects, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
  • Global Indoleamine 2,3 Dioxygenase 1 Market Insights, Forecast to 2025
    Published: 07-Dec-2018        Price: US 3900 Onwards        Pages: 119
    In 2017, the global Indoleamine 2,3 Dioxygenase 1 market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Indoleamine 2,3 Dioxygenase 1 market based on company, product type, application and key regions. This report studies the global market size of Indoleamine 2,3 Dioxygenase 1 in key regions like North America, Europe, Asia Pacific, Central & South America ......
  • Global Integrin Beta 1 Market Insights, Forecast to 2025
    Published: 07-Dec-2018        Price: US 3900 Onwards        Pages: 113
    In 2017, the global Integrin Beta 1 market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Integrin Beta 1 market based on company, product type, application and key regions. This report studies the global market size of Integrin Beta 1 in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the c......
  • Global and Chinese Perphenazines Industry, 2018 Market Research Report
    Published: 07-Dec-2018        Price: US 3000 Onwards        Pages: 146
    The 'Global and Chinese Perphenazines Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Perphenazines industry with a focus on the Chinese market. The report provides key statistics on the market status of the Perphenazines manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition,......
  • Global High Affinity Nerve Growth Factor Receptor Market Insights, Forecast to 2025
    Published: 07-Dec-2018        Price: US 3900 Onwards        Pages: 125
    In 2017, the global High Affinity Nerve Growth Factor Receptor market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the High Affinity Nerve Growth Factor Receptor market based on company, product type, application and key regions. This report studies the global market size of High Affinity Nerve Growth Factor Receptor in key regions like North America, Europe,......
  • Global Fanconi Anemia Drug Market Insights, Forecast to 2025
    Published: 07-Dec-2018        Price: US 3900 Onwards        Pages: 113
    In 2017, the global Fanconi Anemia Drug market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Fanconi Anemia Drug market based on company, product type, application and key regions. This report studies the global market size of Fanconi Anemia Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focu......
  • Global and Chinese 7-Aminocephalosporanic acid (7-ACA) Industry, 2018 Market Research Report
    Published: 07-Dec-2018        Price: US 3000 Onwards        Pages: 135
    The 'Global and Chinese 7-Aminocephalosporanic Acid (7-ACA) Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global 7-Aminocephalosporanic Acid (7-ACA) industry with a focus on the Chinese market. The report provides key statistics on the market status of the 7-Aminocephalosporanic Acid (7-ACA) manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report p......
  • Global Systemic Idiopathic Juvenile Arthritis Treatment Market Insights, Forecast to 2025
    Published: 07-Dec-2018        Price: US 3900 Onwards        Pages: 110
    In 2017, the global Systemic Idiopathic Juvenile Arthritis Treatment market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Systemic Idiopathic Juvenile Arthritis Treatment market based on company, product type, application and key regions. This report studies the global market size of Systemic Idiopathic Juvenile Arthritis Treatment in key regions like Nort......
  • Global Pseudomonas Aeruginosa Pneumonia Drug Market Insights, Forecast to 2025
    Published: 07-Dec-2018        Price: US 3900 Onwards        Pages: 118
    In 2017, the global Pseudomonas Aeruginosa Pneumonia Drug market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Pseudomonas Aeruginosa Pneumonia Drug market based on company, product type, application and key regions. This report studies the global market size of Pseudomonas Aeruginosa Pneumonia Drug in key regions like North America, Europe, Asia Pacific, ......
  • Global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Insights, Forecast to 2025
    Published: 07-Dec-2018        Price: US 3900 Onwards        Pages: 110
    In 2017, the global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 market based on company, product type, application and key regions. This report studies the global market size of Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 in key regions like Nort......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs